Artwork

Conteúdo fornecido por FRONTLINE | PBS. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por FRONTLINE | PBS ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Bribing Doctors, Making Millions

28:38
 
Compartilhar
 

Manage episode 265191215 series 10735
Conteúdo fornecido por FRONTLINE | PBS. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por FRONTLINE | PBS ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
How a drug company made millions pushing an opioid painkiller up to 100x stronger than heroin, as many on Wall Street looked the other way. FRONTLINE filmmaker Tom Jennings and Financial Times reporter Hannah Kuchler discuss their new investigation of Insys Therapeutics — from a jaw-dropping interview with a former sales director who admits to bribing doctors to prescribe the highly addictive drug Subsys, to how Wall Street propelled Insys’ success even as questions emerged about its practices, to what role drug companies’ pursuit of profits has played in the opioid crisis: “I think that it's really interesting just how people are able to disconnect their actions from the consequences, especially in business,” Kuchler says. With federal prosecutors using laws designed to catch mob bosses, Insys would ultimately become the first pharmaceutical company to have its top executives sentenced to prison time in connection with the opioid epidemic. For more on Insys’ spectacular rise and fall — and its consequences — watch the documentary Opioids, Inc. from FRONTLINE and the FT, and read our in-depth joint reporting — also available at ft.com/insys.
  continue reading

155 episódios

Artwork
iconCompartilhar
 
Manage episode 265191215 series 10735
Conteúdo fornecido por FRONTLINE | PBS. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por FRONTLINE | PBS ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
How a drug company made millions pushing an opioid painkiller up to 100x stronger than heroin, as many on Wall Street looked the other way. FRONTLINE filmmaker Tom Jennings and Financial Times reporter Hannah Kuchler discuss their new investigation of Insys Therapeutics — from a jaw-dropping interview with a former sales director who admits to bribing doctors to prescribe the highly addictive drug Subsys, to how Wall Street propelled Insys’ success even as questions emerged about its practices, to what role drug companies’ pursuit of profits has played in the opioid crisis: “I think that it's really interesting just how people are able to disconnect their actions from the consequences, especially in business,” Kuchler says. With federal prosecutors using laws designed to catch mob bosses, Insys would ultimately become the first pharmaceutical company to have its top executives sentenced to prison time in connection with the opioid epidemic. For more on Insys’ spectacular rise and fall — and its consequences — watch the documentary Opioids, Inc. from FRONTLINE and the FT, and read our in-depth joint reporting — also available at ft.com/insys.
  continue reading

155 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências